Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InfuSystems HoldingsINFU -2.30%85 EV-to-EBIT is 19.43 as of Aug. 06, 2026, which is 59% below its 10-year median of 47.17. GuruFocus rates INFU with a GF Score™ of 85/100 and a GF Value™ of $9.25 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 469 Medical Devices & Instruments companies, InfuSystems Holdings ranks worse than 53.73% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
InfuSystems Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $214.5 Mil.
InfuSystems Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InfuSystems Holdings EV-to-EBIT Related Terms
InfuSystems Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for InfuSystems Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, InfuSystems Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InfuSystems Holdings EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InfuSystems Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where InfuSystems Holdings's EV-to-EBIT falls into.
InfuSystems Holdings's current Enterprise Value is $258.7 Mil.
InfuSystems Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InfuSystems Holdings (INFU) has a EV-to-EBIT of 19.43 as of Aug. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on InfuSystems Holdings and its competitors. This is 59% below median its historical median of 47.17. According to the industry distribution chart, InfuSystems Holdings ranks #252 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 53.7%.
Is InfuSystems Holdings' EV-to-EBIT too high?
InfuSystems Holdings' current EV-to-EBIT of 19.43 is 59% below median its 10-year median of 47.17. The Medical Devices & Instruments industry median EV-to-EBIT is 18.89. InfuSystems Holdings' value of 19.43 is 2.9% above this industry median. Based on the distribution chart, InfuSystems Holdings ranks #252 out of 469 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, InfuSystems Holdings has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InfuSystems Holdings' EV-to-EBIT compare to LUCD and QTRX?
According to the Medical Devices & Instruments industry distribution chart, InfuSystems Holdings ranks #252 out of 469 companies for EV-to-EBIT. This places InfuSystems Holdings in the lower half of its industry. The industry median EV-to-EBIT is 18.89. InfuSystems Holdings' value of 19.43 is 2.9% above this benchmark. While the company's 10-year median is 47.17 vs. the industry median of 18.89, InfuSystems Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.89, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InfuSystems Holdings's current EV-to-EBIT of 19.43 is 2.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on InfuSystems Holdings and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InfuSystems Holdings's current EV-to-EBIT is 19.43, which is 59% below median its own 10-year median of 47.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InfuSystems Holdings stock overvalued right now?
Based on GuruFocus' analysis, InfuSystems Holdings (INFU) is currently considered Modestly Overvalued. The stock's GF Value™ is $9.25, compared to a current price of $11.87 — trading 28.3% above its estimated fair value. The current EV-to-EBIT is 19.43, which is 59% below median its 10-year median of 47.17 and 2.9% above the Medical Devices & Instruments industry median of 18.89. InfuSystems Holdings' overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For InfuSystems Holdings (INFU), the current EV-to-EBIT is 19.43 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InfuSystems Holdings (INFU) Overvalued in 2026?
Based on GuruFocus' analysis, InfuSystems Holdings stock appears to be overvalued.
The current stock price of $11.87 is trading 28.3% above its estimated GF Value™ of $9.25.
GuruFocus considers InfuSystems Holdings to be Modestly Overvalued.
Key valuation signals for INFU:
EV-to-EBIT: 19.43 (59% below median its 10-year median of 47.17)
GF Value™: $9.25 vs. price of $11.87 (28.3% above fair value)
Industry Position: 2.9% above the Medical Devices & Instruments median (#252 of 469)
No single metric tells the full story. See the INFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
85GF Score
Get the complete analysis for INFU
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INFU has been successfully added to your 
